Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Acting Treatment in Adolescents
PACTR202302484199604Phase 3Unknown
- Sponsor
- University College London
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University College London. Primary endpoint: Confirmed virological rebound through week 96. Status: unknown.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202302484199604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302484199604.